Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM...

Area of Science:

• Addiction Medicine
• Pharmacology
• Clinical Therapeutics

Background:

• High-dose methadone to buprenorphine transitions for opioid use disorder (OUD) risk precipitated withdrawal due to differing mu-opioid receptor affinities.
• Current literature lacks consensus on optimal buprenorphine microdosing protocols and post-transition patient monitoring.
• Medically supervised settings are crucial for managing complex OUD treatment transitions.

Purpose of the Study:

• To report a feasible 6-day microdosing transition protocol from high-dose methadone to sublingual buprenorphine.
• To describe patient outcomes and withdrawal symptomology during and after the transition.
• To highlight the role of intensive inpatient care in managing OUD treatment transitions.

Main Methods:

• A 6-day sublingual buprenorphine microdosing protocol was initiated directly after 100 mg daily methadone.
• Supportive medications were administered to manage potential withdrawal symptoms.
• The patient was monitored in an American Society of Addiction Medicine (ASAM) level 3.7 intensive inpatient setting for 26 days.

Main Results:

• The patient tolerated the buprenorphine microdosing protocol with supportive care, achieving a peak Clinical Opiate Withdrawal Scale score of 6.
• The most significant withdrawal symptoms emerged several days after the microdosing phase concluded.
• The intensive inpatient setting facilitated comprehensive monitoring and treatment during the acute and post-acute transition phases.

Conclusions:

• Transmucosal buprenorphine microdosing is a feasible strategy for transitioning patients from high-dose methadone.
• Intensive inpatient monitoring (ASAM 3.7) is valuable for managing patients during and after buprenorphine microdosing transitions.
• Withdrawal symptom management requires ongoing attention beyond the initial microdosing period.